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   A clinical trial using human lymphoblastoid interferon （HLBI） was done on patients with
advanced renal cell carcinoma to compare the eflricacy of monotherapy with that of combined
ad1皿inistration witb．a5一且uorouracil（FU）agent．．Atotal of 24 patients with definitely diagnosed
advanced renal cell carcinoma were enrolled in either of the HLBI treatments． Principally， the
daily intramuscular injection of 3 million units of HLBI was done for 4 consecutive days and
thereafter followed by twice of weekly injections． The combined agent used in the present study
was 300 or 600 mg of 5－fluorouracil agent given orally． The eflricacy of HLBI was evaluated
according to direct assessment standard of chemotherapy to a solid tumor expelled by the committee
of Japanese health and welfare ministry． Of 11 patients who received monotherapy， 3 had a partial
response rate of 27．3 percent． While only one of 13 patients having received combined HLBI
administration with oral 5－FU tablets showed a partial response with a response rate of7：7 percent．
A total of 4 patients partially’responded to either HLBI treatment with a subsequent response of
16．7 percent． Partial response implied reduction of lung metastatic foci in 3 patients’and primary
lesion in one patient・ There was observed untoward fever－up in all patients with且LBI injections
which was relieved with acquired tachyphylaxis owing to repeated injections． Otherwise minimal
adverse effects were temporary elevation of liver transaminase’奄?4 and eucopenia in 2 patients
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during the HLBI treatment both of which eventually returned to the normal level without dis－
continuation of HLBI therapy． These clinical results suggest that HLBI treatment are margina11y
effective for the treatment of advanced renal cell carcinoma via a rare reduetion of lung metastasis
and even primary overwhelming renal mass．
                              （Acta Urol． Jpn．．35： 1461－1455， 1989）






























































































































































































































































































































症例数 CR  PR  NC  PD  奏効率
腎摘施行群  11  0  3  7 1 27．3％




























 HLBI単独治療群11例の効果判定は， PR 3例，










症例数 CR  PR  NC  PD  奏効率
単独群 11 0 3 7  1 27．3％
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Fig． L 症例工0の腹部CT scan． A：HLBI
    投与前，B：HLBI投与8週後
 また腎摘施行の有無別での効果判定をみると，腎摘






































の腎癌に施行した結果，16例中，PR 2例， MR 2例
で奏効率が25％であったとする報告もある20）．
 さらにHLBIとUFTの併用療法の結果，10症
例中，NC 5例， PD 5例であったとする報告や2D，
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